Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide once weekly vs insulin glargine once daily as add-on to metformin ± sulfonylurea in insulin-naive type 2 diabetes
2013-004392-12Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of semaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-004392-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004392-12.